Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
cd20-targeting inkt cells
- Development stage
- Preclinical
- Modality
- Cell Therapies
- Administration
- Intravenous
01
Overview
CD20-targeting iNKT cells are engineered invariant natural killer T (iNKT) cells that express a chimeric antigen receptor (CAR) targeting the CD20 antigen found on B cell surfaces. These modified immune cells are designed to recognize and eliminate CD20-positive tumor or pathogenic B cells. The therapy involves ex vivo expansion and genetic modification of patient-derived or donor-derived iNKT cells, followed by intravenous infusion as part of a treatment regimen for malignancies such as B cell lymphomas[1][2]. Each treatment cycle typically includes multiple infusions over several weeks.
- Other names
- 靶向CD20的iNKT细胞CD20-targeting iNKT cellsCD-20-targeting iNKT cellsCD 20-targeting iNKT cells工程化CD20靶向性NKT细胞
02
Targets
Beyond the preview
Go deeper on cd20-targeting inkt cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on cd20-targeting inkt cells.